



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Sarilumab](#) > [Printer-friendly PDF](#)

Sarilumab

Trade Name:

Kevzara

Manufacturer/Distributor:

Sanofi Genzyme Canada

Classification:

Disease modifying anti-rheumatic drug

ATC Class:

L04AC - Interleukin inhibitor

Status:

active

Notice of Compliance (yyyy/mm/dd):

2017/05/30

Date Marketed in Canada (yyyy/mm/dd):

2017/08/16

Presentation:

Injection: 150 mg/1.14 mL. DIN: 02460521

Injection: 200 mg/1.14 mL. DIN: 02460548

Comments:

Sarilumab is an interleukin-6 receptor antibody for treatment of adults with moderate to severe rheumatoid arthritis who have had either an intolerance or inadequate response to one or more DMARDs. The recommended dose of is 200 mg once every 2 weeks given as a subcutaneous injection. Reduction of dose from 200 mg once every 2 weeks to 150 mg once every 2 weeks is recommended for management of neutropenia, thrombocytopenia, and elevated liver enzymes.

Keywords: sarilumab

arthritis: rheumatoid

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:

<Any>

Search Terms:

Apply

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

| <u>Generic Name</u> | <u>Common Trade Name(s)</u> | <u>Classification</u> | <u>Date Marketed in Canada (yyyy/mm/dd)</u> |
|--|-----------------------------|---|---|
| <u>Abatacept</u> | Orencia | Co-stimulation modulator for rheumatoid arthritis | 2006/09 |
| <u>Abemaciclib</u> | Verzenio | Protein kinase inhibitor | 2019/07/03 |
| <u>Abiraterone</u> | Zytiga | Androgen biosynthesis inhibitor | 2011/08/08 |
| <u>Acamprosate</u> | Campral | Alcohol abstinence aid | 2007/03 |
| <u>Acidinium + formoterol</u> | Duaklir Genuair | Bronchodilator combination - LAMA plus LABA | 2015/07/09 |
| <u>Acidinium bromide</u> | Tudorza Genuair | Bronchodilator | 2013-09 |
| <u>Adapalene + benzoyl peroxide</u> | Tactuo | Acne therapy | 2011/04 |
| <u>Adefovir dipivoxil</u> | Hepsera | Antiviral agent | 2006/10 |
| <u>Afatinib</u> | Giotrif | Protein kinase inhibitor | 2014/05/28 |
| <u>Albiglutide</u> | Eperzan | Antihyperglycemic agent | 2016/02/19 |
| <u>Alendronate</u> | Fosamax | Bone resorption inhibitor | 2011/03 |
| <u>Alglucosidase alfa</u> | Myozyme | Enzyme replacement therapy | 2007/04 |
| <u>Aliskiren and hydrochlorothiazide</u> | Rasilez HCT | Renin inhibitor and diuretic | 2009/09 |
| <u>Alitretinoin</u> | Toctino | Immunomodulator, antiinflammatory agent | 2010/10/19 |
| <u>Alogliptin</u> | Nesina | Oral antihyperglycemic agent | 2014/10/08 |
| <u>Alogliptin + metformin</u> | Kazano | Oral antihyperglycemic agent | 2014/10/08 |
| <u>Alpelisib</u> | Piqray | Antineoplastic agent | 2020/03/11 |
| <u>Aluminum chloride hexahydrate</u> | Hydrosal gel | Antiperspirant | |
| <u>Aminophylline</u> | Phyllocontin | Bronchodilator | 2010 |

| <u>Generic Name</u> | <u>Common Trade Name(s)</u> | <u>Classification</u> | <u>Date Marketed in Canada (yyyy/mm/dd)</u> |
|---|-----------------------------|---|---|
| <u>Apalutamide</u> | Erleada | Anti-androgen | 2018/07/27 |
| <u>Apixaban</u> | Eliquis | Anticoagulant | 2012/03 |
| <u>Apomorphine</u> | Movapo | Nonergot-derivative dopamine receptor agonist | 2018/04/xx |
| <u>Apomorphine</u> | Kynmobi | Nonergot-derivative dopamine receptor agonist | 2020/06/12 |
| <u>Apremilast</u> | Otezla | Immunosuppressant agent | 2014/12/08 |
| <u>Aripiprazole</u> | Abilify | Antipsychotic agent | 2009/07/03 |
| <u>ASA + Meprobamate + Codeine + Caffeine</u> | 282 MEP | Narcotic analgesic | |
| <u>Asenapine</u> | Saphris | Atypical antipsychotic | 2012/03/16 |
| <u>Asunaprevir</u> | Sunvepra | Antiviral agent | 2016/04/22 |
| <u>Avelumab</u> | Bavencio | Antineoplastic agent | 2017/12/18 |
| <u>Axicabtagene ciloleucel</u> | Yescarta | Antineoplastic agent | 2019/11/27 |
| <u>Axitinib</u> | Inlyta | Anti-tumor agent | 2012/09 |
| <u>Azacitidine</u> | Vidaza | Antineoplastic agent | 2009/12/07 |
| <u>Azelastine + fluticasone</u> | Dymista | Antihistamine and corticosteroid agent | 2015/10/22 |
| <u>Azilsartan</u> | Edarbi | Antihypertensive agent | 2013/03/27 |
| <u>Azilsartan + chlorthalidone</u> | Edarbyclor | Antihypertensive agent | 2013/03/27 |
| <u>Azithromycin dihydrate</u> | Zmax SR | Antibiotic | 2010/10/29 |

1 2 3 4 5 6 7 8 9 ? next ? last »

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the x?m??k??y??m (Musqueam), Sk?wx?wu?7mesh U?xwumixw (Squamish Nation), and s?!?ilw?ta? (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call

your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-04-12 20:57): <http://www.dpic.org/druglisting/sarilumab>